Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed this ...

Between digital therapeutics, HCP portals, and patient support communications, pharma companies are investing a significant ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

EVERSANA has signed an agreement with Oracle Argus Cloud to add to the features of its pharmacovigilance platform, which ...

In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the ...

Embarking on the journey of a medical start-up is like navigating a complex labyrinth, where the final prize is the coveted ...

At LSX 2024 in Boston last month, editor-in-chief Jonah Comstock spoke with James Graham, CEO and founder of Recce Pharma, an ...

Artificial intelligence (AI) is an increasingly valuable tool in our perpetual quest for the miracles that science regularly ...

For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments. However, ...

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...